Brief: Pediapharm sells its US rights to Naproxen suspension

Medexus Pharmaceuticals

13/01/2016 14:58

Jan 13 (Reuters) - Pediapharm Inc  PDP.V : 
 * Sells its US rights to Naproxen suspension in a transaction valued at up to approximately US$4.25 million 
 * Says the prescription drug user fee assessment ("PDUFA") date is expected to be held in February 2016 
 * Will retain rights to Naproxen suspension in Canada and will continue to commercialize using its own infrastructure 
 * Terms include payment of $2.25 million in cash on closing, payment of $2.0 mnl conditional on Pediapharm being granted approval from FDA 
 
 * Source text for Eikon  urn:newsml:reuters.com:*:nCCNb48wN0 
  
 * Further company coverage  PDP.V  
 
 ((Bengaluru Newsroom; +1 646 223 8780))